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Abstract
Signaling through G protein-coupled receptors (GPCRs) mediates numerous airway smooth
muscle (ASM) functions including contraction, growth, and "synthetic" functions that orchestrate
airway inflammation and promote remodeling of airway architecture. In this review we provide a
comprehensive overview of the GPCRs that have been identified in ASM cells, and discuss the
extent to which signaling via these GPCRs has been characterized and linked to distinct ASM
functions. In addition, we examine the role of GPCR signaling and its regulation in asthma and
asthma treatment, and suggest an integrative model whereby an imbalance of GPCR-derived signals
in ASM cells contributes to the asthmatic state.
Introduction
G protein coupled receptors (GPCRs) comprise a super-
family of proteins capable of transducing a wide range of
extracellular signals across the plasma membrane of the
cell into discrete intracellular messages capable of regulat-
ing numerous, diverse cell functions. Over 800 GPCRs
have been cloned to date and over 1000 are suspected in
the human genome [1]. The majority of all prescribed
drugs target either activation of GPCRs or their down-
stream signals. This holds true for drugs used in the man-
agement of airway diseases such as asthma; it is generally
accepted that GPCRs on airway smooth muscle (ASM) are
the direct targets of the majority of anti-asthma drugs.
Until recently most research efforts examining GPCR ex-
pression, function, and regulation in ASM have focused
on those receptors capable of dynamic regulation of ASM
contractile state and consequently, airway resistance.
However, the growing appreciation of ASM as a pleiotrop-
ic cell capable of regulating airway resistance via "synthet-
ic functions" has provided a much wider context in which
to consider the relevance of numerous ASM GPCRs.
GPCRs whose activation has little or no direct impact on
contractile state may instead modulate ASM growth or the
secretion of various cytokines, chemokines, eicosanoids,
or growth factors that orchestrate airway inflammation
through actions on both mesenchymal and infiltrating
cells. These effects may ultimately influence airway resist-
ance by: 1) promoting airway remodeling that impacts the
mechanics of ASM contraction in vivo; or 2) regulating the
inflammatory response to either disrupt the balance of lo-
cal pro-contractile/relaxant molecules or alter electro- or
pharmaco-mechanical coupling in ASM. Accordingly, it is
no longer permissible to judge the relevance of a given
ASM GPCR based on its ability to dynamically modulate
ASM contractile state and airway resistance. Indeed, our
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newfound appreciation of multiple experimental
endpoints defining ASM function has aided efforts to
identify relevant ASM GPCRs and their signaling
properties.
In this review we will summarize the signaling and func-
tional effects of various GPCRs that have been identified
in ASM cells. In addition, we will consider how the regu-
lation (or dysregulation) of GPCR signaling potentially
impacts asthma pathogenesis and treatment.
Models for analyzing GPCR signaling in ASM
Models for analyzing GPCR signaling in ASM run the
spectrum of integrative to reductionist approaches, each
having certain advantages and disadvantages. Integrative
in vivo models in which GPCR ligands are administered
systemically or through inhalation can suggest the pres-
ence of ASM GPCRs capable of mediating bronchocon-
strictive or relaxant effects. Such experiments can provide
important insight into the role of a given GPCR in regulat-
ing lung resistance, and suggest the utility of targeting a re-
ceptor in order to control bronchospasm. However, the
direct target cell of delivered agents is often unclear, and
frequently the response of ASM is secondary to actions on
other cell types. For example, inhaled agents can provoke
the release of bronchoreactive substances from multiple
cell types that in turn engage ASM GPCRs, or regulate au-
tonomic control of ASM contraction through actions on
pre- or post-ganglionic neurons or reflex arcs [2–4].
A more controlled environment in which to characterize
ASM GPCRs is provided by ex vivo analyses of tracheal or
bronchial smooth muscle isolated as strips or as part of a
complex including cartilaginous ring. This approach re-
duces, but does not eliminate, neural or paracrine effects
on ASM that can dominate functional ASM responses in
vivo. Such effects can persist because preparations still in-
clude autonomic effector and sensory nerve fiber endings,
epithelium, fibroblasts, and blood cells capable of releas-
ing constricting/relaxing agents in response to exogenous
agents or, possibly, mechanical forces [5]. Consequently,
intelligent design of such ex vivo analyses can help clarify
the in vivo effects of numerous agents and identify their
target cells. For example, immunohistochemical analysis
and tissue bath mechanics of excised ASM strips suggest
that the pronounced bronchoconstriction elicited by in-
haled adenosine or adenosine monophosphate in asth-
matic subjects or sensitized animals can be attributed
primarily to histamine release from mast cells in close
proximity to or imbedded in ASM tissue [6–11].
Arguably, the development of ASM cell cultures has pro-
vided the most reliable system for identifying and charac-
terizing ASM GPCRs. Typically generated by enzymatic
dissociation of ASM cells from sections of tracheae or
bronchi, ASM cultures provide a pure population of ASM
cells that can be greatly expanded, and thus are amenable
to extensive pharmacological, biochemical, and molecu-
lar analyses not possible in vivo or with tissues [12,13].
Cells of ASM cultures of several species (including human,
canine, bovine, guinea pig, and mouse) have been shown
to be morphologically and functionally similar to ASM in
vivo; they stain for smooth muscle-alpha-actin and my-
osin heavy chain, and exhibit signaling and functional re-
sponses that are consistent with ASM function observed or
suspected in vivo [12–15].
The power of ASM cultures as an experimental model ca-
pable of verifying existing and identifying new signaling
paradigms, while also establishing their physiologic rele-
vance, is under-appreciated. This power is largely attribut-
ed to the fact that ASM cells possess physiologic levels of
most signaling components (e.g., receptors, effectors, and
downstream signaling intermediates), yet many signaling
pathways are readily characterized with robust signal to
noise ratios. Most importantly, numerous ASM cell func-
tions (including growth, synthesis/secretion of autocrine/
paracrine factors, and to a limited extent, contraction) are
also easily quantified and can be linked to their associated
signaling events. In many other cell culture systems such
linkage of signaling to relevant cell function cannot be
achieved. For example, the majority of studies revealing
novel receptor-mediated signaling paradigms have uti-
lized expression systems such as COS or HEK293 cells to
express recombinant receptors or signaling components
in order to delineate pathway interactions and their
modes of regulation. It is unclear whether such paradigms
occur under relevant conditions in which most signaling
components are expressed at low levels and their actions
may be constrained by compartmentalization [16,17].
Moreover, whether such signaling has any relevance to
cell function is unclear, because such cells typically either
lack discrete measurable functions or their functions are
known to be dysregulated (e.g., physiologic regulation of
growth cannot be studied in a transformed cell). Recent
studies [18–20] have begun testing the applicability and
physiologic relevance of various GPCR signaling para-
digms in cultured ASM cells.
However, ASM cultures as a model system are far from
perfect. That ASM cells in culture lack the context of the in
vivo condition is not only a strength but also an inherent
limitation of this reductionist model. Moreover, like most
primary cells grown in culture, ASM cells undergo a degree
of de-differentiation that coincides with a loss or increase
in various signaling elements and functional apparatus
[3]. Specific changes in ASM cells relevant to GPCR sign-
aling that are known to occur in culture include a rapid
and progressive decrease in the expression of Gq-coupled
receptors such as the m3 muscarinic acetylcholine recep-
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tor (m3 mAChR) [21] and the cysteinyl leukotriene type 1
receptor (CLT1R; Stuart Hirst, personal communication).
In addition, contractile function of cultured ASM cells is
rapidly diminished, coinciding with reduced expression
of smooth muscle alpha-actin and myosin heavy chain,
calponin, h-caldesmon, beta-tropomyosin, and myosin
light chain kinase (MLCK) [22]. However, Shore, Fred-
berg, and colleagues have developed a model for examin-
ing agonist-induced changes in stiffness of cultured ASM
cells that has provided useful information linking regula-
tion of GPCR signaling with ASM contractile state [23]. In-
terestingly, Stephens [24], Halayko, Solway [25–27], and
colleagues have demonstrated that prolonged serum star-
vation of cultured canine ASM cells can beget a subpopu-
lation of cells that reacquire high m3 mAChR and
contractile/cytoskeletal protein expression and thus con-
tractile function. These findings suggest a potentially pow-
erful strategy for delineating elements critical to Gq-
coupled receptor signaling and pharmaco-mechanical
coupling in ASM.
Gq-coupled receptors
Although numerous GPCRs have the ability to couple to
more than one heterotrimeric G protein, a given GPCR is
typically classified based on the G protein subfamily (e.g.,
Gs, Gi/o, or Gq/11) it preferentially activates. A diagram
of Gq-coupled receptor signaling, and the associated func-
tional outcomes in ASM, is provided in Fig. 1. Signaling
via Gq-coupled receptors in ASM is of particular interest
due to its prominent role in promoting ASM contraction.
Transmembrane signaling occurs in the classical GPCR-G
protein-effector protein paradigm. An agonist-bound re-
ceptor undergoes a conformational change that promotes
its association with and activation of the heterotrimeric G
protein Gq. The extreme C-terminus of the G alpha subu-
nit is the receptor recognition domain and dictates recep-
tor-Gα specificity. Receptor-Gα association promotes the
release of GDP from Gα and binding of GTP. The active
GTP-bound Gα dissociates from Gβγ and in turn activates
an effector molecule. The Gβγ heterodimer (numerous
combinations of 7 different β and 12 different γ subunits
exist) also has the capacity to regulate the activity of vari-
ous effectors and numerous other signaling elements (dis-
cussed below). The duration of one cycle of receptor
activation of effector is dictated by the GTPase activity of
Gα, as the hydrolysis of GTP to GDP promotes reconstitu-
tion and membrane localization of the Gαβγ trimer. Tra-
ditionally, alpha subunit GTPase activity was presumed
"intrinsic", but it is now appreciated that this activity can
be regulated by GTPase proteins (GAPs) in a manner sim-
ilar to that demonstrated for small G proteins [28]. Phos-
pholipase C (PLC) is the principal effector of Gq-
mediated signaling. Eleven different isoforms of PLC exist
and exhibit distinct patterns of regulation; members of the
PLCβ subfamily tend to mediate the actions of activated
Gq [29]. Activated PLC hydrolyzes phosphoinositol 4,5-
bisphosphate (PIP2) into 1,2-diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3). The net effect of in-
creased IP3 and DAG levels is to increase intracellular Ca2+
through release from internal stores and influx from
membrane-bound channels [3], and in ASM to activate
the cell's contractile machinery through both Ca2+ and
protein kinase C (PKC) -dependent mechanisms [30–33]
(see Fig. 1 Legend for details).
Studies of agonist-induced increases in airway resistance,
smooth muscle contraction ex vivo, and receptor binding
and second messenger analyses of cultured ASM cells have
helped identify numerous Gq-coupled receptors in ASM
(Table 1). Resting ASM tone in vivo is determined prima-
rily by parasympathetic cholinergic innervation acting on
ASM m3 mAChRs. Other ASM Gq-coupled receptors capa-
ble of inducing significant ASM contraction (in vivo or ex
vivo) include the H1 histamine receptor, CLT1R, B2
bradykinin receptors, and ET-A endothelin receptor. Addi-
tional Gq-coupled receptors such as the A3 adenosine,
NK-1, NK-2 (Neurokinin-1 and -2) and P2 purinergic
have been identified, but their importance in mediating
contraction under physiologic or pathologic conditions is
unclear. In some cases the evidence for their expression in
ASM is either indirect or is difficult to interpret given the
labile nature of Gq-coupled receptor expression in ASM
cultures.
However, as noted above ASM cells do more than contract
and studies of other functional outcomes in ASM suggest
a potentially important role for numerous Gq-coupled re-
ceptors in modulating ASM synthetic functions. Both
thrombin (capable of activating Gq through protease-acti-
vated receptors (PARs) [34]) and lysophosphatidic acid
(LPA) (capable of activating Gq through endothelium dif-
ferentiation gene (EDG) receptors) are strong stimulators
of cultured ASM DNA synthesis and cell proliferation.
These effects appear in part Gq-dependent (Billington and
Penn, unpublished observations) and may be mediated
by the capacity of Gq signaling to stimulate the p42/p44
MAPK (via PKC-mediated phosphorylation of Raf-1) and
p70S6K pathways and therefore induce promitogenic
transcription factor activation, cyclin D1 induction, and
upregulate the translational machinery necessary for cell
cycle progression [36,37]. Moreover, numerous Gq-cou-
pled receptor agonists including thrombin, lysophospha-
tidic acid, leukotriene D4 (LTD4), endothelin, histamine,
thromboxane (activating Thromboxane A2 / Prostagland-
in (TP) receptors)[19], and sphingosine-1-phosphate
(SPP) (activating EDG receptors) have been shown to po-
tentiate the mitogenic effects of receptor tyrosine kinase
signaling, although it has not been established that Gq ac-
tivation per se mediates this effect.
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Figure 1
Gq-coupled receptor signaling in airway smooth muscle. Airway smooth muscle (ASM) is innervated by postganglionic 
parasympathetic nerves that release acetylcholine (acting on m3 mAChRs) to control resting ASM tone. In addition to the m3 
muscarinic acetylcholine receptor (mAChR), other Gq-coupled coupled receptors are expressed in ASM (see Table 1), and can 
similarly mediate contraction and other depicted ASM functions. Transmembrane signaling of G protein-coupled receptors 
(GPCRs) involves sequential activation of receptor, G protein, and effector. Upon agonist binding, the receptor undergoes a 
conformational change exposing a high-affinity binding site for a G-protein in its GDP-bound inactive state. The receptor spe-
cifically interacts with the C-terminus of the α subunit of the G-protein heterotrimer. G-protein binding to receptor releases 
the nucleotide leaving an empty nucleotide binding pocket readily occupied by GTP, which exists at a higher cytosolic concen-
tration than GDP. This exchange of the G-protein-bound GDP for GTP induces a conformational change in the switch region 
of Gα and causes the dissociation of Gα from the Gβγ dimer. The Gβ and Gγ subunits are tightly associated and remain 
anchored into the lipid bilayer due to the prenylation of the Gγ subunit – a permanent lipid modification. In the case of Gαq, 
the GTP-bound Gα q-protein's effector interaction domain is exposed and activates phospholipase C (PLC). PLC promotes 
the hydrolysis of phosphoinositol 4,5-bisphosphate (PIP2) into the intracellular messengers 1,2-diacylglycerol (DAG) and inosi-
tol 1,4,5-trisphosphate (IP3). DAG remains membrane bound and promotes the translocation of protein kinase C (PKC) from 
the cytoplasm to the membrane and its subsequent activation. Activated PKC is capable of phosphorylating a number of sub-
strates including calponin; PKC-mediated phosphorylation of calponin results in a loss of calponin's ability to inhibit actomyosin 
ATPase [30,269]. PKC also phosphorylates intermediates of MAPK signaling pathways, which activate various gene transcrip-
tion factors involved in promoting ASM growth. Gq-coupled receptors are also able to impact receptor tyrosine kinase-
induced ASM growth via a synergistic activation of p70S6K. Both PKC and p42/p44 MAPK phosphorylate and stimulate the cat-
alytic activity of phospholipase A2 (PLA2). Calcium binding to PLA2 triggers its association with the plasma or nuclear mem-
brane and the subsequent cleaving and release of arachadonic acid (AA). The conversion of AA to prostaglandins and 
thromboxanes is facilitated by cyclo-oxygenase-2, a highly regulated enzyme upregulated by pro-inflammatory agents including 
lipopolysaccharide, cytokines and growth factors. The other product of PIP2 hydrolysis, IP3, translocates and binds to IP3 
receptors located on sarcoplasmic calcium stores. Activation of IP3 receptors results in the opening of Ca2+ channels and cal-
cium efflux into the cytosol. Intracellular calcium stores are the major source of elevated calcium mediating ASM contraction, 
although influx from receptor-operated calcium channels can contribute. The rise in intracellular calcium promotes calcium 
binding to calmodulin forming calcium-calmodulin complexes that activate myosin light chain kinase (MLCK). MLCK phosphor-
ylates myosin light chains and enables actin to activate the myosin ATPase activity required for cross-bridge cycling and con-
traction. Via its interaction with various guanine-nucleotide exchange factors for Rho (RhoGEFs), Gq has also recently been 
shown to activate the small G protein Rho [270]. In ASM, Gq-mediated activation of Rho has been implicated in regulating actin 
cytoskeletal rearrangement [40]. Rho is also a key mediator of calcium sensitization – a phenomenon observed following stim-
ulation with numerous GPCRs whereby heightened contractile effects can be induced for a given level of calcium mobilization. 
Rho activates Rho kinase, which in turn phosphorylates the myosin binding subunit of myosin light chain phosphatase (MLCP) 
to inhibit phosphatase activity, resulting in net increased phosphorylation of myosin light chain (MLC) and an associated 
increase in cross-bridge cycling [271]. Although activation of G12/13 is most commonly associated with Rho activity, studies of 
ASM suggest that Gq and Gi can also participate in Rho-mediated functions [40,272,273].
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Gq-dependent activation of PKC and p42/p44 also pro-
motes phosphorylation and activation of phospholipase
A2 (PLA2), which contributes to rapid eicosanoid synthe-
sis in ASM cells stimulated with bradykinin (acting on B2
bradykinin receptors)[39]. Other effects reported to in-
volve Gq activation by ASM GPCRs include actin polym-
erization induced by LPA, endothelin, or carbachol,
which appears to occur via a Rho-dependent mechanism
[40]. This suggests that effectors other than PLC can be di-
rectly activated by Gq in ASM.
Gs-coupled receptors
Whereas Gq-coupled receptors are the principal mediators
of ASM contraction, Gs-coupled receptors on ASM play a
central role in promoting relaxation of contracted ASM
and in conferring prophylactic "bronchoprotection". In-
haled beta-agonists, which activate the Gs-coupled beta-2-
adrenergic receptor (β2AR) on ASM, are the most widely
used agents in asthma therapy and are universally recog-
nized as the treatment of choice for acute asthma attacks.
Several other Gs-coupled receptors, including the E-Pros-
tanoid 2 (EP2) prostaglandin E2 (PGE2) [20], IP prostacy-
clin ([41] and Pascual and Penn, unpublished
observations), A2b adenosine [42], and vasoactive intesti-
nal peptide (VIP)[43] receptors have been identified in
ASM and represent intriguing, albeit elusive, therapeutic
targets (Table 1).
Gs-coupled receptor signaling and its regulation have
been extensively characterized in numerous cells types, in-
cluding ASM [44]. The overwhelming majority of studies
delineating the basic tenets of Gs-coupled receptor signal-
ing have examined β2AR signaling, based on the preva-
lence of endogenously expressed β2ARs, the established
relevance of β2ARs in the function of several organ sys-
tems, the existence of highly selective β2AR ligands, and
the early cloning of the β2AR enabling heterologous ex-
pression of the receptor in various cell systems. Figure 2
depicts the most prominent features of Gs-coupled recep-
tor signaling and functional consequences in ASM cells.
Adenylyl cyclase (AC) is the principal effector of Gs-cou-
pled receptor transmembrane signaling. Nine isoforms
(type I through IX) of AC are known to exist [45]. RT-PCR
has identified transcripts of all AC subtypes except III and
VIII in human ASM cultures, although immunoblot anal-
Table 1: 
GPCR References Couples to Functions in ASM1 Comment
5-HT [125,126,213–215] Gi2 CXN, GP 5-HT2c identified, other subtypes likely
A1 adenosine [42,216,217] Gi CXN Low levels suggested in human ASM
A2b adenosine [42] Gs3 RLXN Mediates effects of autocrine and paracrine adenosine
A3 adenosine [218,219] Gq4 unclear
α-1 adrenergic [220–223] Gq unclear Only response in lung or ex vivo occurs with βAR antagonist 
present
β2 adrenergic [56,185,224,225] Gs RLXN, Cyt, GI
BK bradykinin [39,226–231] Gq CXN Robust activation of PLC and PLA2 in cultured ASM;putative B3 yet 
to be cloned
CLT1R [232–236] Gq CXN, GP CLT1R antagonists most therapeutic of all GqCR antagonists
ET-A/B [237–242] Gq CXN, GP
EDG 1–7 [38,243–245] Gq, Gi, G12/13 GS, Cyt Most subtypes exhibit promiscuity toward G proteins
EP2 [20,246,247] Gs RLXN, GI, Cyt Indirect evidence for expression of EP1, EP3, and EP4
H1 histamine [248,249] Gq CXN, GP Exhibits homologous and heterologous desensitization
IP Prostacyclin [41,250] Gs GI Responsive to autocrine PGI2 induced by cytokines via COX-2 
induction
m2 muscarinic [21,251,252] Gi unclear Mediator of acute adenylyl cyclase inhibition, chronic sensitization
m3 muscarinic [251–256] Gq CXN, GP Rapid reduction of expression in culture
NK-1/2 [257–260] Gq CXN, GP
PAR-1,2,3 [34,261,262] Gq, Gi, G12/13 GS, GP Thrombin most mitogenic GPCR agonist; subtype promiscuity 
towards G proteins
P2 purinergic [218,219] Gq unclear P1 may also be expressed
TP [41,263–266] Gq, Gi, G12/13 
(?)
CXN, GP Coupling specificity poorly characterized in ASM
VIP [43,267,268] Gs GI
1 Abbreviations: CXN – contraction; Cyt – regulation of ASM cytokine/chemokine synthesis; GI-inhibition of ASM growth (DNA synthesis/cell pro-
liferation); GP – potentiation of growth stimulated by polypeptide growth factors; GS – growth stimulation ; RLXN – relaxation 2 Coupling to Gi is 
suggested by sensitivity of signal transduction or functional effects to pertussis toxin 3 All receptors noted to couple to Gs have been shown to 
stimulate cAMP production in ASM. 4 Coupling of receptors to Gq is suggested by either agonist-stimulated phosphoinositide production or cal-
cium flux.
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Figure 2
Gs-coupled receptor signaling in airway smooth muscle. Gs-coupled receptors on airway smooth muscle (ASM) are 
activated by endogenous agents such as circulating catecholamines, prostaglandins and iso-prostanes, adenosine and vasoactive 
intestinal peptide (VIP). Activated Gαs binds to and activates membrane bound adenylyl cyclase (AC). AC is comprised of eight 
membrane-spanning α-helices, and two cytosolic domains which are required for catalytic activity and integrate various regula-
tory signals. The cytosolic domains possess specific binding sites for the G-protein subunits Gαs, Gαi, and Gβγ. Of the nine 
know AC isoforms, AC V and VI appear be expressed and functionally important in human ASM. Adenylyl cyclase activation 
catalyzes the formation of cyclic AMP from cytoplasmic ATP. Cyclic AMP is a ubiquitous second messenger whose principal 
function is to activate protein kinase A (PKA). Inactive PKA exists as a complex comprising two regulatory and two catalytic 
subunits. The high affinity binding of cyclic AMP to domains in the regulatory region induces a conformational change forcing 
the release of the active catalytic subunits. PKA-mediated phosphorylation of various intracellular proteins has widespread 
effects in ASM. PKA can phosphorylate certain Gq-coupled receptors as well as phospholipase C (PLC) and thereby inhibit G 
protein-coupled receptor (GPCR) -PLC-mediated phosphoinositide (PI) generation, and thus calcium flux. PKA phosphorylates 
the inositol 1,4,5-trisphosphate (IP3) receptor to reduce its affinity for IP3 and further limit calcium mobilization. PKA phospho-
rylates myosin light chain kinase (MLCK) and decreases its affinity to calcium calmodulin, thus reducing activity and myosin light 
chain (MLC) phosphorylation. PKA also phosphorylates KCa++ channels in ASM, increasing their open-state probability (and 
therefore K+ efflux) and promoting hyperpolarization. Through its phosphorylation of the transcription factor CREB and its 
(typically inhibitory) effects on GPCR and receptor tyrosine kinase signaling, PKA regulates the transcription of numerous 
genes. Recent studies suggest that cAMP/PKA mediates regulation of the expression of numerous immunomodulatory proteins 
in ASM including IL-6, RANTES, eotaxin, and GM-CSF [53,54,274–276]. Although poorly characterized, the growth inhibitory 
effect of Gs-coupled receptor activation in ASM is consistent with the known effects of PKA on mitogenic signaling. These 
effects include inhibition of p42/p44 MAPK signaling via phosphorylation and inhibition of the upstream intermediate raf-1, and 
via inhibition of promitogenic transcriptional regulation mediated by phospho-CREB. Lastly, Gs-coupled receptor activation is 
also believed to promote PKA-independent effects, including gating of KCa++ channels directly by Gαs [56], and actin polymer-
ization via an unestablished mechanism [55].
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ysis suggests the presence of only V/VI (existing antibodies
do not distinguish between type V and VI), and analyses
of AC regulation in human ASM cultures (discussed be-
low) are consistent with the expression of AC V and VI
[46,47]. Interestingly, AC subtype expression in ASM cul-
tures may be species specific, as regulatory features of AC
in bovine, canine, and guinea pig ASM suggest prominent
expression of AC II [48–51], whereas a minimal [46] or no
[47] level of AC II transcripts were detected in human
ASM (see below).
Adenylyl cyclase isoforms are subject to multiple forms of
regulation (discussed below), although dynamic activa-
tion of AC under physiologic conditions occurs almost ex-
clusively by interaction with Gαs [52]. Gαs activation of
AC catalyzes ATP to cyclic AMP (cAMP), which in turn
binds to the regulatory subunits of the cAMP-dependent
protein kinase (protein kinase A or PKA). The cAMP-
bound regulatory subunits then dissociate from and
thereby activate the catalytic subunits of the enzyme,
which in turn phosphorylate and regulate the activity of
numerous proteins, including the transcription factor
CREB. PKA activity is presumed responsible for the major-
ity of cellular actions elicited by Gs-coupled receptor acti-
vation, which in ASM include relaxation, altered
transcription of numerous genes that impact airway in-
flammation and remodeling [53,54], inhibition of cell
growth, and ion channel gating [3]. However, cAMP/PKA
-independent signaling by Gs-coupled receptors has also
been proposed and may have important functional conse-
quences in ASM. These include beta-agonist-induced actin
depolymerization [55], direct activation of Ca2+-sensitive
K+ channels by Gαs subunits [56], and possibly other ill-
defined signaling events that promote relaxation and are
unaffected by exposure of ASM to pharmacological inhib-
itors of PKA [57].
Gi-coupled receptors
The majority of known GPCRs preferentially couple to
members of the Gi family, and Gi appears to be the most
abundantly expressed heterotrimeric G protein in most
cell types. Members of the Gαi family expressed in ASM
include Gαi-1, Gαi-2, and Gαi-3 [58,59]. Gαi activation is
typically associated with inhibition of Gαs-stimulated AC
activity (for certain AC isoforms) and thus reduced cAMP
generation, the functional consequences of which should
be predictable but are often difficult to identify in a wide
range of experimental models [2,60]. However, numerous
other signaling events elicited by Gαi activation, with
clear functional consequences, have recently been identi-
fied (Fig. 3). Gi appears capable of activating Rho through
activation of Rho guanine nucleotide exchange factors
(GEFs), and in ASM this can mediate both actin polymer-
ization and possibly contractile sensitization [40,61].
Whether Gi activation of Rho is mediated by α or βγ sub-
units is unclear. βγ subunits released due to Gi activation
are believed to promote many of the βγ effects identified
to date, perhaps reflecting the relatively high levels of Gi
in most cells that could provide the levels of free βγ re-
quired for its signaling effect [52]. In in vitro systems βγ
subunits have been shown to enhance the activity of se-
lected AC isoforms stimulated by Gαs. Moreover, βγ may
also mediate, through what may be an indirect mecha-
nism [62], the AC sensitization observed in neuronal cells
chronically exposed to opioids (contributing to tolerance
to morphine [63–65]) and in human ASM cells chronical-
ly treated with carbachol and other ligands capable of ac-
tivating Gi-coupled receptors [46]. The purpose of such
AC sensitization in ASM is unclear, but may involve the
need to maintain a degree of Gs-coupled receptor signal-
ing in the face of persistent Gi-coupled receptor
activation.
A role for Gi-coupled receptors in modulating growth in
ASM is suggested by studies that demonstrate that pertus-
sis toxin (which ADP-ribosylates and inhibits Gαi) par-
tially inhibits ASM DNA synthesis stimulated by
numerous GPCR ligands including carbachol (activating
the m2 mAChR), LPA, SPP, endothelin, and thrombin
[18,38]. The mechanism mediating Gi-stimulated growth
of ASM is unclear, although actions of both α and βγ sub-
units may be involved. Gβγ has the potential to stimulate
p42/p44 MAPK via activation of PLC and PKC, and can
also mediate p42/p44 activation through Src-dependent
transactivation of the epidermal growth factor (EGF) re-
ceptor [66]. However, none of these mechanisms has
been established in ASM. On the contrary, transactivation
of the EGF receptor is not induced by thrombin, carba-
chol, or LPA in human ASM cultures, and increased p42/
p44 MAPK signaling does not appear to mediate the syn-
ergistic effect of several GPCR agonists on EGF-stimulated
ASM growth [18,19]. These latter findings suggest
potentially novel mitogenic signaling events and define
cooperativity between GPCRs and receptor tyrosine kinas-
es in mediating ASM growth.
G12/13 coupled receptors
Signaling via activation of the G12/13 family has not been
characterized as extensively as has that by other heterot-
rimeric G proteins. The effector molecules that interact di-
rectly with G12 and G13 are not well established, with the
exception of members of a family of guanine nucleotide
exchange factors for the small G protein Rho [67]. The
GPCRs capable of activating G12 or G13 are also unclear.
Immunoblot analysis demonstrates Gα12 and Gα13 pro-
tein in rat bronchial smooth muscle tissue, and levels are
elevated by repeated antigen challenge (see below)[68]. In
ASM cells, those GPCRs activating G12/13 have not been
characterized, although SPP/LPA-activated EDG recep-
tors, thrombin-activated PAR receptors, and TP receptors
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are candidates. The profound effect of inhibitors of Rho
and Rho kinase on GPCR-mediated changes in contractile
sensitization [69,70] and actin polymerization [40]
strongly suggest a physiologic role for G12/13 signaling in
ASM.
Regulation of GPCR signaling
Signaling by GPCRs is a highly regulated process. One crit-
ical way in which a cell controls its response to extracellu-
lar GPCR ligands is through regulation of the expression
and activity of each component of the GPCR-G protein-ef-
fector pathway. Either a loss (desensitization) or increase
(sensitization) in responsiveness of transmembrane sign-
aling components can be evoked to presumably preserve
the cell/organism from excessive signals or ensure detec-
tion and reaction to infrequent or minimal signals. In
ASM, studies of regulation of GPCR signaling have fo-
cused on changes that occur in receptor and G protein ex-
pression and second messenger generation in cells, or on
altered contractile/relaxant effects on ASM in vivo or ex vi-
vo. No studies to date have considered the effect of desen-
sitization or sensitization of GPCR signaling on GPCR-
mediated functions in ASM other than contraction.
Figure 3
Gi-coupled receptor signaling in airway smooth muscle. Gi-coupled receptors have the capacity to initiate or modulate 
signaling through the actions of both Gi-derived α and βγ subunits. Activated Gαi dissociates from the heterotrimeric complex 
and binds to adenylyl cyclase (AC) V and VI to act as a negative modulator of Gαs-induced signaling. Gβγ subunits modulate 
AC activity in an isoform-specific manner, inhibiting AC type I but enhancing Gαs-induced activation of AC II, IV and VII. Gβγ 
can also activate phospholipase C beta (PLCβ) isoforms, resulting in phosphoinositide generation, protein kinase C (PKC) acti-
vation via 1,2-diacylglycerol (DAG), and calcium mobilization. Through ill-defined mechanisms, Gi-coupled receptor activation 
can also promote airway smooth muscle (ASM) growth [18], and cooperate with both other G protein-coupled receptors 
(GPCRs) [277,278] and receptor tyrosine kinases [19,243] to synergistically stimulate growth. Lastly, Gi activation in ASM can 
contribute to Rho-dependent changes in actin polymerization [40,279,280] and calcium sensitization [273], although the mech-
anism of Rho activation by Gi in ASM (or other cell types) is not well established.
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Regulation at the receptor locus
Changes in expression or activity of the receptor represent
a powerful means of regulating GPCR signaling. Altered
GPCR responsiveness can occur via altered receptor densi-
ty (up- or down- regulation), modifications of the receptor
such as phosphorylation that diminishes receptor-G pro-
tein interaction (uncoupling), and trafficking of receptor
away from G protein (sequestration/internalization) that en-
ables either recycling of receptor to a responsive form or
facilitates receptor loss by lysosomal degradation (Figure
4). These mechanisms have been characterized extensively
in studies of the β2AR. The degree to which they apply to
other GPCRs is both receptor- and cell-dependent [44]. In
ASM cells, upon exposure to their agonist, both the β2AR
and A2b adenosine receptor undergo rapid desensitiza-
tion [42,71,72], which is defined by a loss in agonist-stim-
ulated cAMP generation, (agonist-specific or homologous
desensitization). Rapid beta-agonist-promoted desensiti-
zation of the ASM β2ARs is mediated primarily by receptor
phosphorylation by G protein-coupled receptor kinases
(GRKs)[44], which specifically recognize the agonist-oc-
cupied form of GPCRs. Numerous GPCRs in various cell
types including ASM [72] have been shown to be regulat-
ed by GRKs, and GRKs themselves are subject to multiple
forms of regulation, some of which may influence GPCR
function in certain disease states (reviewed in [1]). GRK
phosphorylation of GPCRs partially uncouples the recep-
tor from Gα, and also promotes binding of arrestin mole-
cules to the receptor, which more effectively uncouple the
receptor from G protein by sterically inhibiting the recep-
tor-Gα interaction [73]. For numerous GPCRs, GRK-me-
diated arrestin binding also initiates receptor
internalization/sequestration, which occurs via the associ-
ation of the receptor-arrestin complex with components
of clathrin-coated pits [74,75]. GPCR internalization is
not required for GPCR desensitization, but is required for
resensitization, as demonstrated for the β2AR in ASM
[72]. Interestingly, agonist-stimulated arrestin-dependent
internalization of both the β2AR and A2b adenosine re-
ceptor is observed in human ASM cells, whereas ASM EP2
receptors do not readily bind arrestin, do not appear to be
phosphorylated by GRKs, and do not undergo rapid ago-
nist-stimulated internalization [20]. Although ASM EP2
receptors do exhibit desensitization with chronic PGE2
treatment, they are much more efficacious in stimulating
cAMP generation and promoting PKA-dependent func-
tional effects in ASM cells than are either β2ARs or A2b ad-
enosine receptors ([20] and Pascual and Penn,
unpublished observations). These findings demonstrate
the receptor-specific nature of mechanisms of homolo-
gous desensitization, and also show that susceptibility to
desensitization at the receptor locus can be a major deter-
minant in establishing the effect of GPCR ligands and
their receptors on cellular functions.
GPCRs are also subject to phosphorylation and desensiti-
zation by PKA and PKC. Accordingly, any agent capable of
activating cellular PKA or PKC (e.g., other GPCR agonists,
phosphodiesterase inhibitors) can diminish GPCR re-
sponsiveness. PKA and PKC-mediated phosphorylation
causes a degree of receptor uncoupling from G protein,
but it does not promote arrestin binding to receptor and
rapid internalization. Such heterologous desensitization of
a given GPCR is typically not as profound as homologous
desensitization. Cultured ASM cells exposed briefly to ei-
ther PGE2, adenosine, forskolin (all stimulators of cAMP
production and PKA activation) or phorbol ester (a PKC
activator) exhibit diminished isoproterenol-stimulated
cAMP production [42,46,71,72]. Similarly, chronic expo-
sure of ASM cells to interleukin-1β (IL-1β), tumor necrosis
factor alpha (TNF-α), or transforming growth factor beta
(TGF-β) also results in heterologous desensitization of the
β2AR, presumably via the induction of Cyclo-oxygenase-2
(COX-2) activity and the autocrine effect of induced PGE2
[76–80]. The PGE2- or IL-1β-mediated loss of beta-ago-
nist-stimulated second messenger generation is associated
with a loss in the relaxant effect of beta-agonist on carba-
chol-contracted ASM cells in culture [77]. The H1 hista-
mine receptor exhibits both homologous [81] and
heterologous [81] desensitization, the former presumably
mediated exclusively by GRKs, the latter induced by phor-
bol ester in a PKC-dependent manner.
Down-regulation, defined as a loss in receptor density, oc-
curs as a result of increased receptor degradation or re-
duced receptor synthesis. Recovery from GPCR down-
regulation is a relatively slow process and requires new re-
ceptor synthesis. Virtually all GPCRs studied to date un-
dergo some degree of downregulation when chronically
exposed to their agonist. Other agents can promote a loss
of GPCR density through either inhibition of receptor
gene transcription, or via ill-defined mechanisms that
promote receptor degradation.
Arrestin-dependent internalization of GPCRs has been
identified as a pathway leading to lysosomal degradation
of GPCRs [82]. Recently studies also suggest that β2ARs
and CXCR4 receptors are subject to ubiquitination that ul-
timately directs internalized receptor to lysosomes
[83,84], or in the case of mu and delta opioid receptors, to
proteosomal degradation [85]. Chronic exposure of ASM
cells to beta-agonist, or ASM tissue to histamine results in
down-regulation of the β2AR [86] and H1 histamine re-
ceptor [87], respectively. The effects of a receptor's agonist
and other agents (e.g., glucocortoids, cytokines, beta-ago-
nists) on pre- and post-transcriptional regulation of new
receptor synthesis have been characterized for numerous
GPCRs in ASM or lung [81,87–97]. Although receptor
degradation probably plays a prominent role in the down-
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regulation of GPCRs in ASM, the trafficking of GPCRs to
their degradation fate has not been studied in ASM cells.
Up-regulation of GPCR expression is also observed for nu-
merous GPCRs in numerous cell types and is an impor-
tant physiologic means of conferring sensitization of
GPCR signaling. Increased GPCR expression, mediated by
increased gene transcription as well as post-transcription-
al mechanisms, is frequently induced experimentally by
chronic treatment of cells with antagonist. Antagonist-me-
diated up-regulation of GPCRs is relatively unexplored in
ASM cells or tissue, although chronic treatment of rabbits
with atropine has been shown to up-regulate both m2 and
m3 mAChRs in the airway [98]. Transcription regulation
of most GPCR genes in ASM cells is poorly understood,
but should be greatly abetted by the increasing adroitness
in applying molecular techniques to primary ASM cul-
tures and by the emergence of models of ASM phenotype
regulation [27,93].
One final means by which GPCR responsiveness is influ-
enced is by receptor genotype. Single nucleotide polymor-
phisms (SNPs) that result in changes in β2AR expression,
cellular distribution, and signaling have been identified in
both the promoter and coding region of the β2AR gene
[99,100]. SNPs identified in the β2AR promoter have been
shown to affect receptor expression [101,102]. Among
those polymorphisms detected in the coding region,
Arg→Gly16 exhibits enhanced agonist-induced desensiti-
zation (of beta-agonist-stimulated cAMP generation) and
down-regulation, whereas Gln→Glu27 is decidedly de-
sensitization- and down-regulation-resistant. Important-
ly, these properties are evident in β2ARs expressed
endogenously in ASM cultures [86]. SNPs identified in
Figure 4
G protein-coupled receptor regulation in airway smooth muscle. Regulation of G protein-coupled receptor signaling 
at the receptor locus is effected by numerous mechanisms that establish the number and responsiveness of receptors at the 
cell surface. These mechanisms include new receptor synthesis, as well as modes of desensitization and resensitization that 
unfold after a receptor is activated by agonist. Receptor uncoupling occurs as a result of G protein-coupled receptor kinase 
(GRK) -mediated phosphorylation of agonist-occupied receptor, which promotes arrestin binding to phosphorylated receptor 
and steric inhibition of GPCR-G protein interaction. Arrestin binding to receptor also initiates internalization of receptor into 
clathrin-coated pits, after which receptors can traffick to lysosomes for degradation (downregulation) or be dephosphorylated 
and recycled back to the plasma membrane (resensitization). In addition, activation of intracellular kinases such as protein 
kinase A (PKA) or protein kinase C (PKC) can also phosphorylate GPCRs and promote a loss of GPCR-G protein coupling. 
See text for details.
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other GPCRs (including the α2a- [103], α2b- [104], and
β1-adrenergic receptors [105,106]) have also been shown
to be of functional consequence, although their character-
ization has been performed primarily in either cell expres-
sion models or in the cardiovascular system.
The relevance of β2AR SNPs to asthma and asthma thera-
py are discussed below.
Regulation at the G protein locus
Regulation of G protein expression and activity has the
potential to modify GPCR signaling. Gα subunit GTPase
activity is known to be regulated by recently discovered
RGS (regulators of G protein signaling) proteins [107]. Ex-
perimental manipulation of RGS protein expression can
alter GPCR signaling, but the physiologic role of RGS pro-
teins is unclear. Interestingly, GRK2 has been recently
shown to contain an RGS domain that can interact specif-
ically with Gαq and quench its activity [108].
Overexpression of Gα subunits in various cell systems can
enhance GPCR signaling, and the expression of certain Gα
subtypes is altered in various disease state models (see be-
low). In human ASM cells in culture, overexpression of
Gαs increases both basal and Gs-coupled receptor-medi-
ated cAMP production [46]. Whether altered Gα expres-
sion or localization impacts GPCR signaling under
physiologic conditions is somewhat controversial. Endog-
enous expression of G proteins is typically much higher
than that of GPCRs or effectors, suggesting that most
GPCR-G protein-effector signaling is probably limited
more by the expression/activity of the effector or GPCR
than by that of the G protein [109]. However, a growing
appreciation that GPCR signaling may be highly compart-
mentalized [17] suggests that even small changes in Gα
subtype expression may regulate GPCR signaling. Consist-
ent with this notion are observations that exposure of
lung [110–112], ASM strips ex vivo [113,114], or ASM
cultures [50] to various agents can elicit a loss of β2AR
function that is associated with increased expression of
specific Gαi isoforms or decreased expression of Gαs.
Regulation at the effector locus
Although the study of endogenously-expressed GPCR ef-
fectors lags behind that of GPCRs and heterotrimeric G
proteins, the recent cloning of numerous PLC and AC iso-
forms and their analysis in expression systems has facili-
tated insight into the tremendous complexity of effector
regulation. Multiple mechanisms by which PLC activity is
regulated have been demonstrated [115]. PLCβ activity is
greatly influenced by substrate availability; the agonist-
sensitive pool of PIP2 is metabolized several times per
minute [116], meaning that recycling of products of hy-
drolysis, and the activity of numerous enzymes involved
in this process, is critical to PLC activity. Localization of
PLC isoforms to the membrane appears to be regulated by
interaction of pleckstrin homology domains in PLC with
specific phosphoinositides and Gβγ subunits [117,118].
PLCβ2 and PLCβ3 isoforms can be phosphorylated by
PKA, which results in reduced activity [119–121]. Other
PLC isoforms can be phosphorylated by PKC, albeit with
no apparent consequence [115,122]. Interestingly, acti-
vated PLCβ isoforms serve as GTPase-activating proteins
for Gαq and thus participate in negative feedback control
of their activation [123].
Unfortunately our understanding of PLC regulation is de-
rived largely from studies using cell-free models or cellular
expression systems. With the exception of work from Mar-
tin and colleagues [124–126] and Pyne and Pyne [127],
few studies to date have examined PLC signaling and its
regulation in ASM cells.
Studies of AC regulation have been limited by the ex-
tremely low levels of endogenous AC isoform expression,
and by the unstable nature of the AC protein, which has
rendered its purification and characterization problemat-
ic. Detection of endogenous AC protein with currently
available antibodies is often difficult in many cell types
(including ASM), despite the suggestion of specific iso-
form expression in parallel analyses of AC mRNA levels.
However, expression of recombinant AC isoforms has
helped identify some regulatory features of AC
[45,128,129]. AC I, II, III, V, and VII are subject to phos-
phorylation by PKC, which results in their sensitization
[130–134]. Conversely, phosphorylation of AC V and VI
by PKA inhibits AC activity [135–137]. βγ subunits poten-
tiate the stimulatory effect of Gαs subunits on AC II, IV,
and VII [138–140]. Calcium/calmodulim is also a physio-
logic regulator of AC I, III, and VIII; isoforms whose ex-
pression tends to be restricted to the brain and olfactory
epithelium [128].
Adenylyl cyclase (as well as other elements and regulators
of Gs-coupled receptor signaling) and its activity appear
to be concentrated in lipid rafts or caveolae, suggesting
that compartmentalization serves to facilitate initiation or
quenching of GPCR signaling [141,142]. Similarly, com-
ponents of PLC signaling, but not PLC isoforms them-
selves, are also recovered in caveolin-containing
membrane fractions [143].
In ASM, AC regulation is evident but appears species-spe-
cific. Stevens et al. [48] and Pyne and Pyne [127,144]
demonstrated that bradykinin, platelet-derived growth
factor (PDGF), and phorbol ester stimulate cAMP forma-
tion in guinea pig ASM, presumably via a PKC-dependent
enhancement of AC II activation by Gαs. Chronic treat-
ment of canine ASM cultures with carbachol reduced ba-
sal and agonist-stimulated AC activity, an effect that was
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reversed by PKC inhibition [51]. Similar results were ob-
tained in studies of bovine ASM [50]. In contrast, chronic
treatment of human ASM cultures with carbachol (as well
as numerous other agonists of Gi-coupled receptors) pro-
moted AC sensitization but in a PKC-insensitive, pertus-
sis-toxin sensitive manner [46]. This manner of AC
sensitization has been observed in other cell types includ-
ing neuronal cells treated chronically with opioids, and
appears to be an adaptive response (tolerance) to counter-
act persistent Gi signaling [64,145,146]. In an analysis of
heterologously-expressed AC isoforms in COS cells, Nevo
et al [147] determined that chronic Gi activation resulted
in sensitization of AC I, V, VI, and VIII, and reduced activ-
ity of AC II, IV, and VII. Thus, the profile of AC transcripts
and regulatory features of AC in human ASM suggest a
predominance of AC VI or V in human ASM, whereas
PKC-sensitive isoforms, perhaps AC II, may be preferen-
tially expressed in non-human ASM.
Aberrant GPCR signaling and airway 
hyperreactivity
Changes in airway structure and ASM contractile state are
the principal causes of increased airway resistance in asth-
ma. Altered airway composition and architecture affect
airway resistance through mechanisms that are both inde-
pendent of and complimentary to changes in ASM con-
tractile state. Excessive mucous production and edema are
physical impediments to conductance, whereas edema
and increased ASM mass alter airway geometry to amplify
the effect of ASM contraction on airway lumen diameter
[148–154].
ASM contractile state can be viewed as a function of: 1) the
net sum of GPCR-mediated signals that result in establish-
ing the level of the key contractile signaling molecule,
calcium; and 2) the response of the cell's contractile ma-
chinery to calcium. Figure 5 offers a model that proposes
3 levels at which regulation of GPCR-mediated ASM con-
traction is altered in asthma.
Altered GPCR agonist presentation
On one level we can consider the contribution of a dis-
rupted balance of procontractile and prorelaxant stimuli
accessible to ASM, whereby 1) an increase in procontrac-
tile stimuli in the asthmatic airway promotes greater acti-
vation of GPCRs (Gq- and Gi-coupled receptors)
mediating contraction, or 2) a reduction in agonist levels
serving Gs-coupled receptor activation diminishes prore-
laxant signaling. It is well established that numerous
GPCR agonists (e.g., acetylcholine, histamine, and throm-
boxane) capable of evoking ASM contraction are elevated
in the airways of many asthmatics [155–159]. The source
of these agonists may be neural cells (increased parasym-
pathetic discharge caused by numerous factors) inflam-
matory cells (e.g., from mast cells, platelets), or possibly
resident mesenchymal airway cells (including ASM itself).
Exacerbating this condition in asthma is the sloughing of
airway epithelium, which constitutes a loss of diffusion
barrier and may increase ASM access preferentially to pro-
contractile agonists [152,160,161]. These findings strong-
ly suggest that exaggerated procontractile GPCR agonist
presentation to ASM occurs with asthma and contributes
to increased ASM tone. Less certain is whether the levels of
prorelaxant GPCR agonists are suppressed in asthmatics.
Such agents (e.g., catecholamines, certain eicosanoids)
tend to have short half-lives and their local concentrations
are not easily measured. However, it should be recognized
that the loss of airway epithelium in asthma also consti-
tutes a loss of relaxant factors that target either GPCRs
(e.g. PGE2) or other pathways (nitric oxide) in ASM
[152,162–164].
Altered GPCR responsiveness to agonist
On another level we can consider the contribution of al-
tered GPCR responsiveness to a given level of agonist pre-
sented to ASM, such that the sum of GPCR-generated
signals results in higher than normal increases in intracel-
lular calcium. Such altered GPCR responsiveness may re-
sult from either sensitization of Gq- or Gi-mediated
signaling that promotes increased calcium flux, or from
desensitization of Gs-coupled receptor signaling that an-
tagonizes signaling leading to elevated calcium.
Numerous studies suggest that both of these phenomena
occur and contribute to ASM hyperresponsiveness.
Recent findings demonstrate that GPCR-mediated con-
traction of ASM strips ex vivo is augmented by various
"sensitization" strategies [165]. These strategies include
sensitization to allergen in vivo [68,112,166,167] or prior
exposure of ASM strips ex vivo to cytokines, serum from
atopic asthmatics, or immune complexes [113,168–172].
Studies of ASM cells suggest that the observed ASM hyper-
reactivity results in part from an increased calcium flux
mediated by sensitized Gq- or Gi-coupled receptor trans-
membrane signaling. Treatment of ASM cells with IL-1β
or TNF-α causes a significantly greater increase in phosph-
oinositide generation and calcium flux elicited by carba-
chol, bradykinin, or thrombin [173–177]. Mechanistic
studies suggest that up-regulated receptor or G protein ex-
pression may mediate this enhanced response. IL-1β and
TNF-α are both able to increase B2 bradykinin receptor ex-
pression in ASM [174,175]. Treatment of ASM ex vivo
with cytokines, rhinovirus, or asthmatic serum
[114,171,178], in vivo with antigen or IL-1β [112,179], or
ASM cells in culture with TNF-α [180], has been shown to
increase expression of either Gq or specific Gαi isoforms
in either lung or ASM. These latter findings are consistent
with the observation in ASM cells that calcium mobiliza-
tion stimulated by NaF (a nonspecific Gα activator) is in-
creased following chronic treatment with TNF-α, and
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Figure 5
Model of aberrant G protein-coupled receptor signaling in airway smooth muscle contributing to elevated air-
way smooth muscle tone. Within the context of airway remodeling, G protein-coupled receptor (GPCR) signaling leading 
to airway smooth muscle (ASM) contraction may be altered at 3 different levels in the asthmatic airway. First, ASM may be 
exposed to greater levels of GPCR agonists that promote contraction (i.e., those activating Gq- or Gi-coupled receptors), or 
to lower levels of GPCR agonists that mediate prorelaxant signaling (Gs-coupled receptors). Increased levels of procontractile 
agonists can augment contraction, whereas combined stimulation of ASM with multiple Gq/Gi -coupled receptor agonists has a 
synergistic effect on contraction [277]. The sources of both procontractile and prorelaxant agonists include infiltrating inflam-
matory cells (e.g., mast cells releasing histamine, platelets releasing thrombin), postganglionic neurons with exaggerated cholin-
ergic discharge resulting from stimulated reflex arcs or dysregulated m2 muscarinic acetylcholine receptor (mAChR) -mediated 
feedback inhibition [281], and resident airway cells such as epithelium, fibroblasts, and ASM itself. Access of these agonists to 
ASM may be increased by sloughing of airway epithelium. Second, Gq- or Gi-coupled receptor signaling may be sensitized, or 
Gs-coupled receptor signaling desensitized, resulting in an imbalance of signaling promoting increased phosphoinositide gener-
ation and increased calcium mobilization. Third, the contractile response to calcium may be exaggerated due to "augmented 
sensitization" manifested in increased myosin light chain phosphorylation caused by: 1) an imbalance of GPCR-derived signals; 
and 2) increased expression and activity of myosin light chain kinase (MLCK) associated with inhibited myosin light chain phos-
phatase (MLCP) activity, the latter a result of increased RhoA activity mediated by upregulated G12/13 and RhoA expression. 
Not included in this model (for the sake of simplicity) are other potential regulatory features of ASM contraction including 
ASM strain and load, direct contribution of non-GPCR signaling pathways to phospholipase C (PLC) activation and calcium 
mobilization, calcium loading in intracellular stores, compartmentalization of calcium and calcium signaling, and ion channel and 
membrane pump activity that directly and indirectly affect intracellular calcium levels.
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suggest a mechanism by which calcium flux stimulated by
numerous GPCRs may be augmented [181]. However, it
should be noted that the effects of cytokines on GPCR-
mediated PLC activity can be receptor-specific; in the
same model that demonstrates TNF-α-mediated augmen-
tation of bradykinin-stimulated phosphoinositide pro-
duction, the phosphoinositide response to histamine was
depressed, presumably via a COX-dependent, PKA-medi-
ated phosphorylation and desensitization of the H1 hista-
mine receptor [175].
The contribution of desensitized prorelaxant Gs-coupled
receptor signaling to airway hyperresponsiveness in asth-
ma is unclear. To date, the β2AR is the only Gs-coupled re-
ceptor whose role in asthma has received significant
attention, and the preponderance of evidence suggests
that β2ARs on ASM are most responsible for the effect of
beta-agonists on airway tone [182]. Whether β2AR dys-
function, and specifically β2AR dysfunction in ASM, plays
a prominent role in asthma has been a hotly debated topic
for over thirty years. Asthma triggers such as viral infec-
tions can diminish β2AR function [183], and numerous
animal models of airway inflammation, ex vivo analyses
of ASM strips treated with cytokines or asthmatic serum
[112,114], and limited data from ASM tissue from severe
asthmatics [184,185] have all provided evidence that
β2AR-mediated relaxant effect and signaling are depressed
in asthma. Several possible mechanisms by which the pro-
posed diminished β2AR function and signaling occurs can
be proposed. The diminished capacity of beta-agonists to
inhibit methacholine-induced contraction of ASM strips
ex vivo may reflect an increased capacity of m2 mAChRs
to inhibit beta-agonist-stimulated AC activity (note that
asthmatic serum and cytokines upregulate Gαi expres-
sion). As noted above, several studies also demonstrate
that numerous agents (e.g. cytokines, TGF-β, PGE2, whose
levels are elevated in the asthmatic airway) induce desen-
sitization of the β2AR in cultured ASM cells, typically by
mechanisms suggestive of PKA-mediated β2AR phosphor-
ylation. Moreover, intratracheal installation of IL-1β in
rats results in not only a loss of beta-agonist-mediated re-
laxation of methacholine-induced bronchoconstriction,
but an increase in GRK activity, and GRK2 and GRK5 ex-
pression in the lung [112]. This is an intriguing finding
and suggests that inflammation may modulate homolo-
gous GPCR desensitization in the airway. This may prefer-
entially affect β2AR signaling in ASM, in light of findings
by McGraw et al. suggesting that low (endogenous) ex-
pression levels of GRKs in ASM cells account for relatively
robust β2AR signaling in ASM [186], and that such signal-
ing may be sensitive to changes in GRK [72] or arrestin
[20] expression.
In contrast to the evidence cited above, numerous studies
have noted no appreciable loss of β2AR function in asth-
matics based on analyses of lung function, or tissues ex
vivo (reviewed in [2,4,187]). Moreover, β2AR blockade in
normal subjects does not cause bronchoconstriction
[188,189], and the Arg→Gly16 (desensitization-prone)
β2AR polymorphism is not over-represented in asthmatics
[190]. These findings suggest that asthma is not defined
by diminished β2AR responsiveness. However, constitu-
tive β2AR signaling does appear to be important in the
asthmatic subject, as administration of β2AR antagonists
is not well tolerated in many asthmatic subjects [189].
Predictably, diminished β2AR function could influence
disease severity. Results from both clinical trials and epi-
demiological studies suggest that β2AR SNPs at codon 16
influence β2AR responsiveness to both endogenous and
exogenous beta-agonists and thereby influence disease se-
verity and response to therapy [99,191,192]. Asthmatics
homozygous for Gly16 may have fewer responsive β2ARs
as a result of greater down-regulation caused by endog-
enous catecholamines. Consequently, the effects of en-
dogenous catecholamines and the initial response to
exogenous beta-agonist may be diminished in these pa-
tients, as suggested by data from Martinez et al., demon-
strating a significantly greater bronchodilator response in
(beta-agonist naïve) Arg16 homozygotes [192]. Alterna-
tively, continuous use of inhaled beta-agonists results in a
progressive drop in morning peak flow only in patients
homozygous for the Arg16 SNP [193], suggesting that the
absolute loss of β2AR responsiveness is greater in Arg16
homozygotes because of their greater capacity to down-
regulate from the (naïve) untreated state.
Thus the collective evidence suggests that β2AR dysfunc-
tion of any nature does not cause asthma, but the active
disease state likely promotes a loss of β2AR function that
has a small impact on disease severity, at least in some
subset of asthmatics. As a corollary, β2AR polymorphisms
that diminish β2AR signaling are disease modifiers, but
not disease predictors, and influence the response to ther-
apy. In contrast, a more significant role in asthma is sug-
gested for sensitized Gq or Gi-coupled receptor signal
transduction that promotes a greater phosphoinositide
generation and calcium mobilization in response to a giv-
en concentration of agonist.
Altered responsiveness of the contractile machinery to 
calcium
On a final level we can propose a role for altered respon-
siveness of ASM contractile machinery to calcium as a
mechanism of airway hyperresponsiveness. Although
Rho-mediated sensitization to calcium occurs within the
context of ASM contraction under normal conditions,
there is evidence that calcium sensitization mechanisms
may be primed ("augmented sensitization") by inflam-
mation. Chiba et al. noted that acetylcholine-induced iso-
metric tension was greater in bronchial rings from
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antigen-challenged rats compared to that from control
rats, although no significant difference between the two
groups in calcium mobilization is observed [194]. Simi-
larly, when calcium concentrations were clamped to 1 µM
in permeabilized bronchial rings, tension development
was greater in rings from allergen sensitized/challenged
rats compared to that from controls [70]. Changes in the
expression of numerous proteins may underlie this aug-
mentation of calcium sensitization in ASM. In tracheal
and bronchial smooth muscle from ragweed-sensitized
dogs, a constitutive increase in phosphorylation of my-
osin light chain 20 (MLC20) associated with increased
content and activity of MLCK [195,196], and human
bronchial rings sensitized with allergen ex vivo exhibit an
~3 fold increase in MLCK expression [197]. RhoA protein
levels are increased, and acetylcholine-induced transloca-
tion of RhoA to the plasma membrane is significantly
higher in bronchial smooth muscle from airway hyperre-
sponsive versus control rats [70,198]. Finally, Gα12 and
Gα13 (upstream regulators of Rho activity) levels in bron-
chial smooth muscle are also upregulated in hyperrespon-
sive rats [68]. These data suggest that allergen-driven
inflammation up-regulates multiple proteins in the path-
way promoting Rho-dependent calcium sensitization,
and that augmented calcium sensitization may be suffi-
cient to confer airway hyperreactivity in asthma.
Altered GPCR responsiveness with therapy
To further complicate the relationship between GPCR re-
sponsiveness and asthma, evidence suggests that both glu-
cocorticoids and beta-agonists, the two most widely used
drugs in the treatment of asthma, also regulate GPCR re-
sponsiveness, primarily via changes in receptor expression
and coupling. Glucocorticoids have been shown to up-
regulate β2AR and Gαs expression [89,91,199], counteract
the β2AR down-regulation induced by beta-agonist [92],
and reverse increases in GRK activity and β2AR desensiti-
zation induced in a rat model of airway inflammation
[58]. Conversely, glucocorticoids inhibit expression of
NK2 receptors in bovine ASM [94], inhibit m2 mAChR ex-
pression in the airway [200], and inhibit the IL-1β-medi-
ated up-regulation of B2 bradykinin (BK) receptors in the
airway [201]. Pretreatment of human ASM cells with glu-
cocorticoids significantly inhibits histamine-stimulated
phosphoinositide production [202]. Thus the sum of ef-
fects of glucocorticoids on GPCR signal transduction com-
ponents tends to render ASM less responsive to
procontractile stimuli and more responsiveness to beta-
agonists.
Beta-agonist therapy, on the other hand, tends to promote
the sensitization of procontractile GPCR signaling and de-
sensitization of prorelaxant GPCR signaling, with uncer-
tain clinical relevance. Although conflicting data exist as
to whether beta-agonist therapy exacerbates bronchial hy-
perresponsiveness in asthmatics, Mak and colleagues have
recently demonstrated that exposure of ASM ex vivo to
beta-agonist up-regulates both NK2 [95] and H1 hista-
mine [90] receptors, suggesting a mechanism whereby en-
hanced procontractile GPCR signaling promotes
bronchial hyperresponsiveness.
Numerous studies have also demonstrated that repeated
use of inhaled beta-agonists results in a loss of the prophy-
lactic bronchoprotection conferred by beta-agonists
[203–206]. In many respects this could be considered a
normal and predictable response, consistent with a phys-
iologic/teleologic role of β2AR desensitization and the
demonstration of homologous desensitization of ASM
β2ARs in multiple in vivo, ex vivo, and in vitro models.
However, Finney et al. recently observed that lung GRK2
levels were elevated in rats chronically treated with beta-
agonists [110]. Thus, in a manner similar to that invoked
by IL-1β (see above), chronic beta-agonist therapy may up
regulate the GPCR desensitization "machinery" to further
limit the effect of therapy and possibly exacerbate disease.
Although the clinical relevance of the observed loss of
bronchoprotection has been questioned [207], the collec-
tive evidence suggests that homologous β2AR desensitiza-
tion does occur as a consequence of beta-agonist therapy.
Accordingly, therapies that minimize or counteract β2AR
desensitization, such as glucocorticoids and salmeterol,
may benefit from this property. Glucocorticoids preserve
or enhance β2AR function in the airway through both
their anti-inflammatory actions as well as their direct ef-
fects on ASM β2AR expression and regulation noted
above. These effects may explain in part the positive coop-
erativity exhibited by combined beta-agonist and gluco-
corticoids therapy. As a low intrinsic activity beta agonist,
salmeterol has limited capacity to promote homologous
β2AR desensitization in in vitro models [208,209]; this
property in addition to its lipophilic nature appears large-
ly responsible for its long-lasting effect. Moreover, daily
salmeterol treatment has little effect on the rescue or pro-
phylactic ability of albuterol [203,210].
GPCRs in ASM: What lies ahead
Within the last decade the field of GPCR signaling has ex-
perienced an epiphany with the realization that GPCRs do
more than subserve restricted functions in fully differenti-
ated cells; they also play important roles in mediating di-
verse cell functions such as embryogenesis, tissue
regeneration, and cell proliferation [211,212]. Interesting-
ly, this realization coincided with a similarly profound
discovery in the field of asthma research – that ASM not
only contracts, but also performs numerous "synthetic"
functions that modulate both airway structure and airway
inflammation. Not surprisingly, ASM GPCRs are impor-
tant regulators of many ASM synthetic functions.
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The newfound respective focuses of GPCR signaling and
ASM research suggest an exciting direction for the study of
GPCRs in ASM over the next decade. The current challenge
(or curse) confronting the student of ASM signal transduc-
tion extends beyond defining the myriad intracellular sig-
naling pathways, their regulation, and their degree of
"cross-talk" with each other, to understanding how these
events occur within an equally complex, dynamic airway
environment.
Such an understanding should not only greatly improve
our knowledge of asthma pathogenesis, but also redefine
asthma therapy. With the possible exception of steroids,
asthma drugs have been developed and prescribed to pre-
vent or reverse acute bronchospasm with little considera-
tion of their effects on ASM synthetic functions and the
chronic nature of asthma. As the roles of airway remode-
ling and ASM synthetic functions in asthma pathogenesis
become more clearly established, agents that target the ac-
tivation or signaling of various GPCRs that mediate these
phenomena will undoubtedly receive greater considera-
tion as prophylactic and therapeutic asthma drugs.
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